Polyether Ionophore Intramammary Delivery for Mastitis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for mastitis, particularly in dairy cattle, are ineffective against multi-resistant bacteria like MRSA and MRSP, and existing antimicrobials face challenges due to resistance and toxicity issues, leading to an urgent need for new drugs and delivery systems that are safe and reliably effective.
Innovation Solution
The use of polyether ionophores, such as salinomycin, narasin, and lasalocid, administered intramammarily through the teat canal, to treat and prevent mastitis by providing sustained antibacterial activity with minimal systemic absorption, thus overcoming resistance and toxicity limitations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If β-lactam antimicrobials are used to treat Staphylococcus bacteria, then bactericidal activity is achieved by inhibiting cell wall biosynthesis, but antimicrobial resistance develops through β-lactamase enzyme secretion
Solution Approach 1:
The patent extracts and eliminates the harmful β-lactamase enzyme function by administering a β-lactamase inhibitor (such as clavulanic acid, sulbactam, or tazobactam) that specifically binds to and inactivates the enzyme, thereby removing the resistance mechanism while preserving the β-lactam antimicrobial's bactericidal activity
Solution Approach 2:
The patent creates a composite antimicrobial formulation combining a β-lactam antimicrobial (penicillin, cephalosporin, or carbapenem) with a β-lactamase inhibitor, where the two components work synergistically - the β-lactam provides bactericidal activity while the inhibitor protects it from enzymatic degradation, overcoming resistance without compromising efficacy
2Object-affected harmful factors
If methicillin and other β-lactam antimicrobials that are not inactivated by β-lactamases are used, then resistance to penicillin and its analogues is addressed, but MRSA isolates with mutated PBPs remain resistant
Solution Approach 1:
The patent changes the chemical parameters of the antimicrobial approach by selecting β-lactam compounds with specific side-chain modifications (such as anti-staphylococcal penicillins like flucloxacillin or cephalosporins with extended spectra) that have altered binding characteristics to mutated PBPs, thereby maintaining affinity and bactericidal activity against MRSA strains
Solution Approach 2:
The patent formulates a composite preparation combining a modified β-lactam antimicrobial (designed to resist PBP mutation effects) with a β-lactamase inhibitor, creating a dual-mechanism approach that addresses both the enzymatic resistance and the altered target site resistance simultaneously
3Duration of action of moving object
If polyether ionophores are administered intramammarily, then sustained antibacterial activity is achieved with minimal systemic absorption, but the complexity of delivery system increases
Solution Approach 1:
The patent applies preliminary action by formulating the polyether ionophore in a sustained-release matrix or encapsulated delivery system that is pre-prepared and designed to release the antimicrobial agent gradually over time, eliminating the need for repeated administrations while maintaining therapeutic levels at the infection site
Solution Approach 2:
The patent introduces an intermediary sustained-release formulation system (such as biodegradable polymers, liposomes, or hydrogels) that mediates between the polyether ionophore and the mammary gland tissue, controlling the release kinetics and ensuring sustained local concentration while minimizing systemic exposure
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively inhibits bacterial growth and reduces mastitis symptoms, offering a safer and more reliable treatment option by minimizing systemic toxicity and addressing antibiotic resistance.
Implementation Method 1
Carboxyl polyethers, also known as polyether antibiotics or polyether ionophores, form electrically neutral complexes with monovalent or divalent cations, catalysing electrically silent exchanges of cations or protons across a variety of biological membranes.
Data Source
AI summary
The invention includes methods and compositions for treating mastitis in a subject. The method includes the step of administering, by intramammary delivery, a therapeutically effective amount of a polyether ionophore, or a therapeutically acceptable salt thereof, to the mammary gland of the subject.